Innovative Medicines Initiative to give boost to Europe's pharmaceutical industry

With the launch of its first call for proposals, the Innovative Medicines Initiative (IMI) got underway on 30 April. Joining forces, the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) hope to bring Europe back to the forefront of medical innovation.

Over the next five years, those two primary partners in the IMI Joint Undertaking (IMI JU) will invest €1 billion each, with an initial €123 million being channelled into research projects already in the 2008 funding period.

Following ARTEMIS (Embedded Computing Systems), ENIAC (Nanoelectronics Technologies 2020) and Clean Sky (Aeronautics and Air Transport), IMI is the fourth Joint Technology Initiative (JTI) to be launched.

IMI's scientific priorities determined by the European Commission and the EFPIA for this first call for proposals are the following:

  • improve predictivity of immunogenicity;
  • non-genotoxic carcinogenesis;
  • expert systems for in silico toxicity prediction;
  • improved predictivity of non-clinical safety evaluation;
  • qualification of translational safety biomarkers;
  • strengthening the monitoring of the benefit/risk of medicines;
  • islet cell research;
  • surrogate markers for vascular endpoints;
  • pain research;
  • new tools for the development of novel therapies in psychiatric disorders;
  • neurodegenerative disorders;
  • understanding severe asthma;
  • chronic obstructive pulmonary disease (COPD) patient recorded outcomes;
  • European Medicines Research Training Network;
  • safety sciences for medicines training programme;
  • pharmaceutical medicine training programme;
  • integrated medicines development training programme;
  • pharmacovigilance training programme.

EU Science and Research Commissioner Janez Potocnik in his speech expressed the hope that as many stakeholders as possible would get involved in the initiative in order to 'make Europe a very attractive place for pharmaceutical research and development' once again.

Europe's pharmaceutical industry still produces 35% of the world's pharmaceutical output, making it the second largest player in medicines manufacturing behind the US. The industry is also an important contributor to the European labour market: In 2004, the number of employed exceeded 612,000 with 103,000 highly-skilled employees in the research area.

However, Europe has lost a lot of ground in the area in recent years. Commissioner Potocnik stressed the fact that Europe once used to be called 'the world's pharmacy' with seven out of ten new medicines developed and produced in Europe some ten years ago. Today, however, a mere three out of ten new medicines come from Europe.

"IMI is about pooling public and private efforts so that Europe can be a big player," Mr Potocnik underlined. "We want to be the best in the world and become a champion's league for biopharmaceutical research by moving from individual project-funding to joint programme funding involving industry and public stakeholders."

Speaking on behalf of the EFPIA, the federation's president Arthur Higgins pointed out that there is a growing concern in society about the need to spark pharmaceutical innovation. At the same time, the pharmaceutical industry is faced with increasing regulatory hurdles in a strategy of risk avoidance, he said, adding that "there cannot be therapeutic roses without thorns."

Meanwhile, the average cost for bringing a pharmaceutical product to the market has risen to approximately €1 billion. In addition, the challenges in biomedical sciences were increasingly more complex. "We are the first to admit that we cannot solve all of these problems alone," said Mr Higgins. He therefore called on all stakeholders including small and medium-sized enterprises (SMEs), academia, research centres, patient groups, public authorities and the research-based pharmaceutical industry to actively participate in new JTI.

For further information, please visit: http://imi.europa.eu/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...